Proteogenomic discovery of <i>RB1</i>-defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targets.

Among the RBNSig-OV–high group, both RB1 -defective and RBness subgroups showed a trend of better OS compared to the RBNSig-low group indicating increased chemosensitivity, but this was not statistically significant ( RB1 defective: HR = 0.7, 95% CI = 0.43 to 1.14, P = 0.148; RBness: HR = 0.68, 95% CI = 0.43 to 1.07, P = 0.098; Fig. 5B ).

also in 53,322 other papers